

Nucala Order Form (mepolizumab)

FAX TO: 817-472-7213

PATIENT INFORMATION				
Patient Name:	DOB:	Phone:	Sex: M F Ht:	Wt: lbs kg
Primary Language:A	llergies:			
Patient Preferred Location:				
<icd 10="" code="" required=""> DIAGNOSIS & CLINICAL INFORMATION</icd>				
ICD 10 Code D72.119 Hypereosinophilic Syndrome (HES) J33.8 Other Polyp of Sinus J45.50 Severe Persistent Asthma, Uncompli J45.51 Severe Persistent Asthma, w/Acute E J45.52 Severe Persistent Asthma, w/Status // M30.1 Polyarteritis w/Lung Involvement (Chu	cated Exacerbation Asthmaticus urg-Strauss: EGPA)	abruptly upon	Information tinue systemic or inhaled corticos initiation of therapy. Nucala shou acute asthma symptoms or acute	ld <u>NOT</u> be
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS:</u> Blood eosinophil level OR CBC with differential AND pulmonary function test prior to initiating therapy.				
PRESCRIPTION*				
NUCALA (mepolizumab)				
Loading Dose (SELECT ONE) SubQ: Inject 100 mg every 4 weeks for one year SubQ: Inject 300 mg every 4 weeks for one year (EGPA & HES dosing)				
Pediatric Dose (aged 6-11 years old) SubQ: Inject 40 mg every 4 weeks for one year				
Is the patient on any other disease modifying therapy? Yes No If yes, please note therapy and last dose:				
Post Treatment Observations: The patient is observed for 30 minutes following the first administration.				
Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol. Comments:				
PRESCRIBER INFORMATION				
Prescriber Name: Signature:				
Date: NPI #:				
Supervising Physician:				(If Applicable)
Address:	City:		State:	Zip:
Contact Name:	_ Phone:	Fax:	Email:	